Phase I study of docetaxel combined with carboplatin in patients with non-small cell lung cancer.
- Author:
Li-Ming ZHU
1
;
Qiu-Yun LI
;
Xin-Min YU
;
Shen-Ling MA
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Carboplatin; administration & dosage; adverse effects; Carcinoma, Non-Small-Cell Lung; drug therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; drug therapy; Male; Middle Aged; Neutropenia; chemically induced; Remission Induction; Taxoids; administration & dosage; adverse effects
- From: Chinese Journal of Oncology 2006;28(12):946-948
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the maximum tolerated dose (MTU) and dose-limiting toxicity (DLT) of Docetaxel and Carboplatin in patients with non-small cell lung cancer.
METHODSDocetaxel was given at escalating doses until MTD was determined from the initial dose of 65 mg/m2 to 75 mg/m2, 85 mg/ m2 on dl. Carboplatin was targeted to an area under the plasma concentration curve of 5 using Calver's equation on dl. The treatment cycle was repeated every 3 weeks.
RESULTS16 patients received TXT and CBP for total of 54 courses (median four courses). Neutropenia was the dose-limiting toxicity. The MTD of TXT is 85 mg/m2.
CONCLUSIONWe recommend TXT 75 mg/m2 on d1 and CBP with a target AUC of 5 on d1, 3weeks repeated for chemotherapy in naïve patients with NSCLC.
